Product Description
Bevacizumab Biosimilar
Mechanisms of Action: VEGF Inhibitor
Novel Mechanism: No
Modality: Antibody
Route of Administration: Intravenous
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Company: TRPHARM
Company Location: Europe
Company Founding Year: 2013
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: Colorectal Cancer|Liver Cancer
Phase 2: Non-Small-Cell Lung Cancer|Peritoneal Cancer|Clear Cell Sarcoma|Clear Cell Adenocarcinoma|Carcinosarcoma|Mucinous Adenocarcinoma|Transitional Cell Carcinoma|Endometrioid Carcinoma|Ovarian Cancer|Mesothelioma
Phase 1: Healthy Volunteers|Oncology Unspecified|Sarcoma|Breast Cancer|Ovarian Cancer|Prostate Cancer|Soft Tissue Cancer|Pancreatic Cancer|Acute Myelomonocytic Leukemia|Precursor B-Cell Lymphoblastic Leukemia-Lymphoma|Lymphoma, Non-Hodgkin|Precursor Cell Lymphoblastic Leukemia-Lymphoma|Myeloproliferative Disorders|Lymphoma, B-Cell|Chronic Lymphoid Leukemia|Anemia, Refractory|Thrombocytosis|Breast Diseases|Chronic Myeloid Leukemia|Multiple Myeloma|Acute Myeloid Leukemia|Myelodysplastic-Myeloproliferative Diseases|Adenocarcinoma|Preleukemia|Chronic Myelomonocytic Leukemia|Myelodysplastic Syndrome|Acute Monocytic Leukemia|Acute Lymphoid Leukemia|Leukemia, Plasma Cell|Blast Crisis|Myelofibrosis|Myeloid, Accelerated Leukemia|Juvenile Myelomonocytic Leukemia,|Myelogenous, Chronic, BCR-ABL Positive Leukemia|Lymphocytic Chronic B-Cell Leukemia|Chronic, Atypical, BCR-ABL Negative Myeloid Leukemia|Non-Small-Cell Lung Cancer
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT05238831 |
STUDY00020679 | P1 |
Withdrawn |
Sarcoma|Soft Tissue Cancer|Pancreatic Cancer|Prostate Cancer|Ovarian Cancer|Breast Cancer |
2026-05-31 |
4% |
2024-11-27 |
Primary Endpoints|Treatments |
NCT03878524 |
PRIME | P1 |
Terminated |
Myeloproliferative Disorders|Acute Myelomonocytic Leukemia|Blast Crisis|Lymphocytic Chronic B-Cell Leukemia|Preleukemia|Chronic Myelomonocytic Leukemia|Anemia, Refractory|Precursor Cell Lymphoblastic Leukemia-Lymphoma|Chronic Myeloid Leukemia|Prostate Cancer|Precursor B-Cell Lymphoblastic Leukemia-Lymphoma|Chronic, Atypical, BCR-ABL Negative Myeloid Leukemia|Myelofibrosis|Adenocarcinoma|Thrombocytosis|Pancreatic Cancer|Breast Diseases|Myelogenous, Chronic, BCR-ABL Positive Leukemia|Acute Lymphoid Leukemia|Juvenile Myelomonocytic Leukemia,|Myeloid, Accelerated Leukemia|Myelodysplastic Syndrome|Acute Myeloid Leukemia|Lymphoma, Non-Hodgkin|Leukemia, Plasma Cell|Chronic Lymphoid Leukemia|Lymphoma, B-Cell|Myelodysplastic-Myeloproliferative Diseases|Acute Monocytic Leukemia|Multiple Myeloma|Breast Cancer |
2020-12-10 |
2024-11-27 |
Primary Endpoints|Treatments |
|
NCT03659305 |
СL01011063 | P1 |
Completed |
Oncology Unspecified|Healthy Volunteers |
2019-01-26 |
64% |
2019-03-22 |
Primary Completion Date|Study Completion Date|Treatments|Trial Status |
NCT03131700 |
RPH001BEV01 | P1 |
Withdrawn |
Healthy Volunteers |
2018-01-01 |
2019-03-21 |
Treatments |
|
2017-001634-26 |
2017-001634-26 | P1 |
Unknown status |
Non-Small-Cell Lung Cancer |
2017-05-29 |
2025-06-20 |
Primary Completion Date|Start Date|Study Completion Date|Treatments|Trial Status |
|
NCT07288034 |
IMMUNO-BIOMAP | P2 |
Not yet recruiting |
Non-Small-Cell Lung Cancer |
2028-09-22 |
2025-12-18 |
Primary Endpoints|Treatments |
|
NCT05001880 |
NCI-2021-08573 | P2 |
Recruiting |
Mesothelioma |
2026-08-20 |
2025-10-10 |
Primary Completion Date|Primary Endpoints|Study Completion Date |
|
NCT02364713 |
MC1365 | P2 |
Terminated |
Peritoneal Cancer|Clear Cell Adenocarcinoma|Ovarian Cancer|Carcinosarcoma|Endometrioid Carcinoma|Mucinous Adenocarcinoma|Transitional Cell Carcinoma|Clear Cell Sarcoma |
2022-01-13 |
2025-08-27 |
Patient Enrollment|Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments|Trial Status |
|
NCT05863195 |
The PUMP Trial | P3 |
Recruiting |
Liver Cancer|Colorectal Cancer |
2029-06-30 |
2024-11-27 |
Primary Endpoints|Treatments |
Recent News Events
Date |
Type |
Title |
|---|
